In the biotech sector, Incyte (INCY) and Biogen (BIIB) are showing significant growth and potential. Incyte reported a substantial increase in Q2 revenue of $1.67 billion, exceeding estimates, with strong performance from its new drugs and an acquisition that bolsters its pipeline. Currently, it aims to transition from heavy reliance on its flagship drug Jakafi to a more diversified portfolio by 2030. Biogen, meanwhile, reported revenue of $2.74 billion, also beating expectations, primarily due to growth in its new drug portfolio and recent acquisitions. It is currently facing challenges with its legacy multiple sclerosis treatments but has strong growth potential looking forward. Both stocks are in upward trends, making them noteworthy options in the biotech landscape.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.cnbc.com/2026/08/03/two-biotech-names-on-josh-browns-best-stocks-list-are-making-meaningful-highs-this-summer.html
